Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Irinotecan in ISG15-positive Advanced NSCLC
NCT01654081Phase 2Withdrawn
- Start
- Oct 2013
- Primary completion
- May 2014
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of irinotecan in non-small cell lung cancer (NSCLC). Planned start Oct 2013; status: withdrawn.
02
Drugs
irinotecan
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT01654081.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01654081.